PRA Health Sciences expands remote clinical study support with its Mobile Health Platform during COVID-19 pandemic
25 March 2020 - 7:05AM
As a response to the ongoing global COVID-19 pandemic, PRA Health
Sciences announced today the expansion of its industry-leading
Mobile Health Platform for remote clinical monitoring, adding
several new capabilities that address sponsor needs for COVID-19
virtual study support.
PRA’s Mobile Health Platform (MHP) engages with patients
wherever they are. The app-based platform allows sponsors to do
everything that’s possible in a physician’s office or clinical
site, virtually. The new capabilities added to address COVID-19 are
designed to support clinical trial sponsors and sites participating
in clinical studies by allowing them to connect and coordinate with
patients who are no longer able to travel to sites due to the
current pandemic. Additionally, the mobile app can also be deployed
to transition existing traditional, paper-based studies into more
decentralized, siteless studies so that medical care and the
evaluation of patients can continue during critical study
timeframes.
The mobile app features an administrative web app for
investigators and sites, and a downloadable mobile app for
patients, enabling sites to:
- eConsent/re-consent patients for use of the mobile
application
- Collect consent forms from patients to allow for delivery of
investigational product through a third party courier
- Remotely schedule and conduct video consults with
patients
- Leverage mobile survey tools to provide real-time insights to
study investigators for potential action
“As the COVID-19 pandemic continues, it will be increasingly
difficult for patients to see their medical professionals in person
or adhere to clinical study protocols requiring visits to sites and
hospitals. Equally challenging and difficult is the ability
for sites to keep up with both trial patients as well as COVID-19
patients,” said Kent Thoelke, Executive Vice President and Chief
Scientific Officer at PRA Health Sciences. “This mobile and remote
solution allows critical studies to continue, where protocols and
regulatory guidelines permit, and ensures that patient safety and
wellbeing can be maintained during a time when social distancing
and relieving the burden on our healthcare system is important in
fighting COVID-19.”
The mobile app has the ability to gather electronic informed
consent and e-signatures, and complete patient reported outcomes —
right from the patient’s personal phone or tablet. Using connected
devices, the app also can collect home healthcare data and serve
that data into the source for the clinical trial.
PRA’s Mobile Health Platform is built with each specific trial
in mind and can be rapidly deployed in as little as one week or
less. Depending on the disease state, the patient population, and
sponsor targets, PRA’s clinical technology experts will help
determine what features are most applicable for each particular
hybrid or decentralized trial.
To learn more about the PRA Mobile Health Platform, visit
https://prahs.com/pra-mobile-health-platform. Contact our
team here: https://prahs.com/contact/virtual.
ABOUT PRA HEALTH SCIENCES PRA (NASDAQ: PRAH) is
one of the world’s leading global contract research organizations
by revenue, providing outsourced clinical development and data
solution services to the biotechnology and pharmaceutical
industries. PRA’s global clinical development platform includes
more than 75 offices across North America, Europe, Asia, Latin
America, South Africa, Australia and the Middle East and more than
17,500 employees worldwide. Since 2000, PRA has participated in
approximately 4,000 clinical trials worldwide. In addition, PRA has
participated in the pivotal or supportive trials that led to U.S.
Food and Drug Administration or international regulatory approval
of more than 95 drugs.
INVESTOR INQUIRIES: InvestorRelations@prahs.com
MEDIA INQUIRIES: Laurie Hurst, Director, Communications and
Public RelationsHurstLaurie@prahs.com, +1.919.786.8435
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Jun 2024 to Jul 2024
PRA Health Sciences (NASDAQ:PRAH)
Historical Stock Chart
From Jul 2023 to Jul 2024